Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Allogene Therapeutics, Inc. have bought $5M and sold $158,820 worth of Allogene Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Allogene Therapeutics, Inc. have bought $6.97M and sold $28.82M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Belldegrun Arie (director) — $5M. Parker Geoffrey M. (CHIEF FINANCIAL OFFICER) — $2,049.
The last purchase of 1,724,137 shares for transaction amount of $5M was made by Belldegrun Arie (director) on 2024‑05‑16.
2024-12-09 | Sale | director | 9,136 0.0042% | $2.18 | $19,916 | -5.73% | ||
2024-12-05 | Sale | director | 9,221 0.0044% | $2.16 | $19,917 | +2.34% | ||
2024-06-18 | Sale | director | 18,641 0.008% | $2.28 | $42,488 | +18.39% | ||
2024-05-30 | Sale | director | 11,200 0.0051% | $2.34 | $26,181 | +6.10% | ||
2024-05-16 | director | 1.72M 0.9747% | $2.90 | $5M | -13.50% | |||
2024-01-30 | CHIEF FINANCIAL OFFICER | 190 0.0001% | $3.60 | $683 | -21.93% | |||
2023-12-18 | Sale | director | 18,640 0.0103% | $2.70 | $50,317 | -0.69% | ||
2023-08-07 | Sale | director | 10,000 0.0069% | $4.29 | $42,855 | -25.59% | ||
2023-02-13 | Sale | General Counsel | 3,000 0.002% | $6.85 | $20,550 | -40.59% | ||
2023-01-17 | Sale | General Counsel | 3,000 0.0021% | $7.04 | $21,120 | -31.37% | ||
2022-12-15 | Sale | General Counsel | 5,602 0.0041% | $7.53 | $42,186 | -29.66% | ||
2022-08-11 | Sale | 15,000 0.0106% | $16.75 | $251,250 | -61.71% | |||
2022-08-02 | Sale | EVP of R&D and CMO | 2,000 0.0013% | $11.97 | $23,940 | -47.84% | ||
2022-07-05 | Sale | EVP of R&D and CMO | 2,000 0.0014% | $11.44 | $22,880 | -38.52% | ||
2022-06-22 | Sale | 10,000 0.0069% | $11.76 | $117,600 | -33.78% | |||
2022-06-21 | Sale | EVP of R&D and CMO | 2,000 0.0014% | $11.18 | $22,360 | -30.17% | ||
2022-05-19 | Sale | EVP of R&D and CMO | 11,500 0.0079% | $7.40 | $85,092 | +18.54% | ||
2022-03-15 | Sale | President and CEO | 23,648 0.0164% | $7.65 | $180,879 | +21.54% | ||
2022-03-15 | Sale | General Counsel | 8,849 0.0062% | $7.68 | $67,962 | +21.54% | ||
2022-03-15 | Sale | EVP of R&D and CMO | 5,169 0.0036% | $7.71 | $39,848 | +21.54% |
Belldegrun Arie | director | 1724137 0.8223% | $1.90 | 4 | 0 | <0.0001% |
Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 819590 0.3909% | $1.90 | 1 | 0 | |
Humer Franz B | director | 307507 0.1467% | $1.90 | 1 | 2 | +2.3% |
MESSEMER DEBORAH M. | director | 157629 0.0752% | $1.90 | 0 | 3 | |
PFIZER INC | 10 percent owner | 22032040 10.5079% | $1.90 | 1 | 0 | +2.3% |
TPG Group Holdings (SBS) Advisors, Inc. | 10 percent owner | 18716306 8.9265% | $1.90 | 1 | 17 | +2.3% |
Chang David D | President and CEO | 2289652 1.092% | $1.90 | 1 | 3 | +2.3% |
Bhavnagri Veer | General Counsel | 577677 0.2755% | $1.90 | 0 | 16 | |
Amado Rafael | EVP of R&D and CMO | 540257 0.2577% | $1.90 | 0 | 9 | |
Kazam Joshua A | director | 258885 0.1235% | $1.90 | 1 | 0 | <0.0001% |
WITTE OWEN N. | 218271 0.1041% | $1.90 | 1 | 5 | +2.3% | |
MOORE ALISON | Chief Technical Officer | 120430 0.0574% | $1.90 | 0 | 14 | |
SCHMIDT ERIC THOMAS | Chief Financial Officer | 100546 0.048% | $1.90 | 0 | 8 | |
Mayo Stephen | director | 25328 0.0121% | $1.90 | 0 | 1 |
Fidelity Investments | $113.38M | 12.17 | 25.36M | +0.48% | +$546,676.53 | 0.01 | |
Tpg Gp A Llc | $83.66M | 8.98 | 18.72M | 0% | +$0 | 1.62 | |
BlackRock | $43.15M | 4.63 | 9.65M | -3.49% | -$1.56M | <0.01 | |
State Street | $41.05M | 4.41 | 9.18M | +278.37% | +$30.2M | <0.01 | |
The Vanguard Group | $36.69M | 3.94 | 8.21M | -9.12% | -$3.68M | <0.01 | |
PRIMECAP Management Co | $24.35M | 2.62 | 5.45M | +3.15% | +$744,254.99 | 0.02 | |
JPMorgan Chase | $23.16M | 2.49 | 5.18M | -24.97% | -$7.71M | <0.01 | |
T. Rowe Price | $18.68M | 2.01 | 4.18M | +76.16% | +$8.07M | <0.01 | |
Boxer Capital, LLC | $17.21M | 1.85 | 3.85M | New | +$17.21M | 0.35 | |
Citadel Advisors LLC | $13.92M | 1.49 | 3.11M | -23.19% | -$4.2M | 0.01 | |
Frazier Life Sciences Management L P | $12.82M | 1.38 | 2.87M | New | +$12.82M | 0.58 | |
Woodline Partners LP | $11.77M | 1.26 | 2.63M | +2.19% | +$252,447.73 | 0.1 | |
Geode Capital Management | $10.6M | 1.14 | 2.37M | +1.55% | +$161,570.86 | <0.01 | |
Morgan Stanley | $9.98M | 1.07 | 2.23M | +33.83% | +$2.52M | <0.01 | |
Dimensional Fund Advisors | $9.13M | 0.98 | 2.04M | +33.11% | +$2.27M | <0.01 | |
Wildcat Capital Management | $7.88M | 0.92 | 1.92M | 0% | +$0 | 2.86 | |
Two Sigma | $8.54M | 0.92 | 1.91M | -17.42% | -$1.8M | 0.01 | |
Vida Ventures Advisors Llc | $8.04M | 0.86 | 1.8M | 0% | +$0 | 4.47 | |
Two Sigma Advisers LP | $5.95M | 0.64 | 1.33M | +4.18% | +$238,698.00 | 0.01 | |
Goldman Sachs | $5.79M | 0.62 | 1.29M | -61.21% | -$9.13M | <0.01 | |
Rafferty Asset Management Llc | $4.43M | 0.48 | 990,703 | +332.61% | +$3.4M | 0.01 | |
Northern Trust | $4.34M | 0.47 | 971,067 | -4.27% | -$193,452.64 | <0.01 | |
Charles Schwab | $3.84M | 0.41 | 858,476 | +17.14% | +$561,615.31 | <0.01 | |
Nordea Investment Management Ab | $3.38M | 0.36 | 742,114 | +0.19% | +$6,518.20 | <0.01 | |
Octagon Capital Advisors LP | $3.22M | 0.35 | 720,000 | New | +$3.22M | 0.02 | |
Citigroup | $3.03M | 0.33 | 678,229 | +1,875.96% | +$2.88M | <0.01 | |
UBS | $2.32M | 0.25 | 519,201 | +186.54% | +$1.51M | <0.01 | |
Zacks Investment Management | $2.06M | 0.22 | 459,800 | +17.16% | +$301,085.64 | 0.02 | |
Td Asset Management Inc | $1.96M | 0.21 | 437,436 | +83.92% | +$892,212.04 | <0.01 | |
Caxton Associates | $1.93M | 0.21 | 431,186 | -44.37% | -$1.54M | 0.09 | |
Cerity Partners | $1.9M | 0.2 | 424,169 | -18.05% | -$417,551.54 | 0.01 | |
Coastal Bridge Advisors Llc | $1.82M | 0.2 | 406,847 | 0% | +$0 | 0.37 | |
Bank of America | $1.81M | 0.19 | 404,382 | +22.21% | +$328,518.26 | <0.0001 | |
Renaissance Technologies | $1.77M | 0.19 | 396,900 | -13.46% | -$275,991.31 | <0.01 | |
Mirae Asset Global Investments Co Ltd | $1.77M | 0.17 | 361,913 | +85.14% | +$812,904.26 | <0.01 | |
Nuveen | $1.35M | 0.15 | 302,255 | -15.47% | -$247,204.44 | <0.0001 | |
BNY Mellon | $1.34M | 0.14 | 300,553 | -7.23% | -$104,723.09 | <0.0001 | |
Susquehanna Fundamental Investments Llc | $1.28M | 0.14 | 286,408 | New | +$1.28M | 0.06 | |
The Manufacturers Life Insurance Company | $1.26M | 0.14 | 282,150 | +37.48% | +$343,814.66 | <0.01 | |
Mitsubishi UFJ Kokusai Asset Management | $972,203.00 | 0.1 | 217,495 | -1.63% | -$16,087.54 | <0.01 | |
Swiss National Bank | $960,156.00 | 0.1 | 214,800 | 0% | +$0 | <0.01 | |
Millennium Management LLC | $900,571.00 | 0.1 | 201,470 | -89.5% | -$7.68M | <0.01 | |
Prudential Financial | $886,901.00 | 0.1 | 198,412 | -47.63% | -$806,512.58 | <0.01 | |
D. E. Shaw & Co. | $875,127.00 | 0.09 | 195,778 | +158.83% | +$537,016.45 | <0.01 | |
PDT Partners | $844,955.00 | 0.09 | 189,028 | +1,085.58% | +$773,685.33 | 0.06 | |
Ameriprise Financial | $845,008.00 | 0.09 | 189,040 | -0.66% | -$5,609.85 | <0.0001 | |
Ubs Asset Management Americas Inc | $761,184.00 | 0.08 | 170,287 | +8.66% | +$60,693.75 | <0.0001 | |
ExodusPoint Capital Management, LP | $729,000.00 | 0.08 | 163,023 | -64.78% | -$1.34M | 0.01 | |
Los Angeles Capital Management LLC | $717,985.00 | 0.08 | 160,623 | -3.23% | -$23,936.86 | <0.01 | |
Barclays | $700,000.00 | 0.08 | 156,747 | -15.23% | -$125,756.79 | <0.0001 |